The Rise of Designer Babies: Polygenic Embryo Selection and the Future of Reproduction

“If I give you a diagnostic tool that lets you finish up with a kid that has a three times higher chance of getting admitted to MIT, I think people are going to be interested.” This statement, made by Stephen Hsu, a physics professor at Michigan State University and co-founder of Genomic Prediction, encapsulates the allure – and the ethical concerns – surrounding polygenic embryo selection. Once the realm of science fiction, as depicted in the 1997 film Gattaca, this technology is rapidly becoming a reality, prompting a critical debate about the future of reproduction and the potential for genetic stratification.

What is Polygenic Embryo Selection?

Companies like Genomic Prediction, Orchid, Herasight, and Nucleus now offer polygenic embryo selection, a technology that assesses embryos based on their genetic makeup to predict future traits. This differs significantly from preimplantation genetic testing (PGT), which screens for chromosomal abnormalities and single-gene disorders like cystic fibrosis and sickle cell anemia. Polygenic embryo selection aims to provide insights into a broader spectrum of traits, including intelligence, predisposition to certain diseases (like heart disease and depression), and even physical characteristics.

How Does it Work?

The technology relies on polygenic scores, which summarize the combined influence of thousands of genetic variants to estimate the likelihood of a trait developing. Even as these scores are valuable research tools for understanding the genetic basis of diseases, their predictive accuracy varies considerably. Currently, they are often unreliable for predicting individual outcomes, especially for complex traits.

Research indicates that many effects captured in polygenic scores aren’t directly biological, but rather reflect correlations between genetics, socioeconomic factors, and geographic location. These scores are less accurate for individuals of non-European ancestry due to biases in the genomic data used to create them. A 2023 study in Nature highlights the limitations and potential for inaccuracies in current polygenic scores.

Ethical and Social Concerns

Despite these limitations, companies are marketing polygenic embryo selection as a responsible approach to family planning. However, the potential consequences are significant:

• Reinforcing Genetic Elitism: Selecting embryos based on polygenic scores could reinforce the belief that children conceived through this method are inherently “better,” mirroring the dystopian society portrayed in Gattaca.
• Heightened Expectations: Parents may place unrealistic expectations on children selected for specific traits.
• Social Stratification: Individuals not selected through this process could face discrimination and stigma, exacerbating existing social inequalities.
• Genetic Arms Race: The pursuit of “optimal” offspring could lead to a genetic arms race, further encoding social and economic disparities into our DNA.

The history of using genetic science to justify harmful and inaccurate views, particularly regarding race, serves as a stark warning.

Regulatory Landscape

The lack of regulation surrounding polygenic embryo selection is a major concern. There are no standardized criteria for determining when the underlying science is accurate enough for clinical employ. Transparency regarding the scientific basis of these services is limited, and misleading advertising faces minimal repercussions. This regulatory void has led companies to establish themselves in the United States, where oversight is less stringent.

In contrast, countries like the United Kingdom, Germany, and France have banned polygenic embryo selection, recognizing the risks of unchecked market forces. While loopholes exist, these nations have taken a more cautious approach.

Accessibility and Equity

Currently, polygenic embryo selection is financially inaccessible to most Americans. It requires in vitro fertilization (IVF), which can cost tens of thousands of dollars per cycle and is not covered by Medicaid. Adding genetic testing for each embryo further increases the financial burden.

As the technology improves, the existing wealth gap in the United States could translate into biological inequalities, with affluent families having the means to “optimize” their offspring. Investment from tech elites, including Alexis Ohanian (Reddit co-founder) and Brian Armstrong (Coinbase co-founder), as well as interest from figures like Sam Altman (OpenAI) and Elon Musk (Tesla), demonstrates the growing financial backing of this industry.

Looking Ahead

As genomic databases grow and turn into more diverse, the accuracy of polygenic scores will likely improve. However, crucial ethical and social questions remain unanswered: What traits should parents be allowed to select? How can we prevent unreasonable expectations for children conceived through this technology? Regulation is essential to ensure that scientific progress benefits society as a whole, rather than exacerbating existing inequalities.